Answers are grounded in this paper and cite their sources.
Background/Objectives: Human milk oligosaccharides (HMOs) are bioactive glycans that may influence neurodevelopment through microbiota-dependent and independent pathways. This systematic review critically evaluates neuroimaging evidence linking HMO exposure to brain structure, microstructural organization, and neurochemical profiles, integrating imaging-derived outcomes with proposed molecular mechanisms and assessing their translational relevance to human infants. Methods: PubMed, MEDLINE, and Scopus were systematically searched from database inception to November 2026 for human and animal intervention studies investigating HMO-associated neuroimaging outcomes. Evidence was narratively synthesized according to HMO composition, dosage, developmental stage, imaging modality, and methodological quality. Results: Eight eligible intervention studies were identified, all involving neonatal piglets; no human intervention studies met the neuroimaging eligibility criteria. Magnetic resonance spectroscopy findings suggested that sialylated HMO formulations were associated with positive changes in selected cerebral metabolites. Combined HMO and lactoferrin supplementation was also associated with altered regional metabolite profiles, although their independent contributions remain uncertain. Structural MRI, diffusion tensor imaging, and myelin-sensitive imaging findings were heterogeneous, predominantly region-specific, and frequently nonsignificant. Potential mechanisms involving microbial metabolites, Sia availability, ganglioside metabolism, neural cell adhesion molecule polysialylation, neuroinflammation, and synaptic plasticity, remain hypothesis-generating rather than causally established. Conclusions: Current preclinical evidence suggests that HMO-containing interventions may influence selected neuroimaging outcomes but does not establish consistent improvements in neurodevelopment. Methodological heterogeneity limits cross-study comparisons and the absence of eligible human intervention studies limit clinical translation. Longitudinal investigations integrating neuroimaging, molecular profiling, and functional assessments are needed to clarify the imaging-based neurodevelopmental relevance of HMOs.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: